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In economic theory, homo economicus is a concept used to explain decision-making as a
rational exercise.1 The “economic man”, to use the term often associated with the work of
the utilitarian philosopher John Stuart Mills, is someone who makes decisions by carefully
weighing the benefits and costs of his options, then deciding on a course of action that
maximizes his utility. Although now considered overly simplistic, this idea is often implicit
in how we as clinicians have traditionally approached medical decision-making. In the case
of statins for the primary prevention of cardiovascular diseases, the choice is frequently
framed in terms of the trade-off between the potential benefit of preventing a future heart
attack or stroke (i.e., utility) versus the side effects and inconveniences of taking a
medication (i.e., disutility). Thus the recently released 2013 American Heart Association /
American College of Cardiology Guideline on the Treatment of Blood Cholesterol reminds
us that, in addition to calculating estimated atherosclerotic cardiovascular disease (ASCVD)
risk to determine statin eligibility, we should engage with patients “in a discussion… to
consider the potential for ASCVD benefit and for adverse effects, for drug-drug interactions,
and patient preferences for treatment.”2 Yet, while much of the debate over the current
guidelines has focused on the accuracy of risk estimation,3, 4 the evidence base is limited for
how to engage with patients during the decision making process to assess their disutility for
taking statin therapy.
This is in part because although the proportion of patients who report side effects can be
measured, it is difficult to assign a numeric value to the aspect of disutility resulting from
having to take a medication daily. In this issue of Circulation, Fontana and Asaria and
colleagues address this issue by surveying a random sample of 360 individuals encountered
on London throughfares.5 Describing a hypothetical medication that has negligible costs and
no side effects, the investigators used a time-trade off approach to ask the participants how
much this medication must add to their lifespan before they are willing to take it daily.
Medication disutility, measured in this way, was found to have a bimodal distribution. While
a third of the individuals surveyed had minimal medication disutility and were willing to
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take the hypothetical medication even if the benefit was less than a month, 12% of
participants reported the highest level of medication disutility that the survey was able to
measure, and would refuse the hypothetical medication even if they could gain more than 10
years of life.
These findings should not surprise most clinicians, who often encounter patients resistant to
the very idea of taking medications. Nonetheless, as the authors note, all too often disutility
is assumed to be nearly zero for statins, for example in published cost-effective analyses that
have drawn favorable conclusions for broadening statin use.6, 7 The basis for this
assumption is unclear, though it appears to have been extrapolated from very low level of
disutility for warfarin and aspirin observed in previous studies of patients with atrial
fibrillation.8, 9 The present study by Fontana and Asaria and colleagues is therefore an
important step forward, both for its development of a tool to quantify medication disutility
and for its provocative finding that a significant minority of individuals in the general
population may have high levels of medication disutility.
How might these results influence the day-to-day decision of whether to recommend
primary prevention statin therapy to individual patients? The authors provide some guidance
by using the SCORE algorithm10 to calculate the distribution of estimated longevity benefit
from statin therapy for various demographic and cardiovascular risk subgroups of the
general UK population. The estimated longevity benefit for taking statins, when calculated
in this way, ranges from 5.5 months to 24.3 months of added lifespan for men, and 3.6 to
18.2 months for women. Although these findings suggest that many individuals will have
medication disutility that are numerically higher than their estimated longevity benefit, the
authors are appropriately cautious to infer that this comparison should determine eligibility
for statins at the individual level, for several reasons. Since cardiovascular risk factors were
not collected during the survey, estimated longevity benefit could not be calculated at the
individual level for this study. However, even if the data collection was complete, a direct
comparison of estimated longevity benefit against medication disutility would be
problematic. To see this, consider the hypothetical example of two individuals, A and B,
both of whom are 60 years-old men, don’t smoke, have systolic blood pressure of 140
mmHg and total cholesterol of 5 mmol/L, and have medication disutility quantified as 5
years. Using Figure 3 provided by the authors, the longevity benefit associated with statin
therapy is 7.4 months for both of these men, and is much lower than their medication
disutility. Individual A stays off statins, never experiences a cardiovascular event, and is
happy that he was able to avoid a lifelong course of preventive medications. Individual B,
however, has a fatal heart attack at age 65 that could have been prevented by taking a statin,
and loses an extra 15 years of lifespan. In his case, it would be hard to justify the decision to
not offer him statin therapy on the grounds that his medication disutility greatly outweighed
his estimated longevity benefit.
The point of this example is not that medication disutility should not be a part of the
decision making process for statin therapy, but that, due to the inherent uncertainty for
estimating any particular individual’s cardiovascular risk, a direct comparison of medication
disutility and estimated longevity benefit can be misleading. At an epistemological level,
regression based methods such as the SCORE algorithm10 and the Pooled Cohorts Equation
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recommended by the recent guidelines2 can only arrive at an averaged risk for all
individuals who share the same risk profile, and therefore can not predict with certainty
whether any given individual will go on to have a cardiovascular event.11 Furthermore, there
has been recent recognition that uncertainty in cardiovascular risk estimation can be caused
by the poor concordance between different risk equations,12 and by variability in the factors
used to estimate risk, such as the variability in systolic blood pressure13 or the level of C-
reactive protein.14
On the other side of the utility equation, the determination of patient preferences such as
medication disutility is also fraught with uncertainty. Just as framing and cognitive biases
affect perceptions of risks,15 medication disutility is also likely to be fluid and context
dependent.16 The substantial differences between the level of medication utility described
here compared with those expressed by atrial fibrillation patients in previous studies8, 9
could in part be due to differences in how the questions were asked (concerning a
hypothetical tablet versus familiar medications, aspirin or warfarin) and the settings in which
participants were interviewed (in public space versus a research office). Finally, the mere
quantification of medication disutility does not address the deeper question of why. When
faced with a patient who is resistant to taking medications that could have important health
benefits, a truly patient-centered approach would require the insightful physician to explore
the reasons, such as whether the concerns are justified misgivings for our overreliance on
medications to treat lifestyle diseases,17 or whether the disutility represent fears about side
effects that are misperceived or misattributed.18
In the social and behavioral sciences, it has been increasingly recognized that rational
decision-making is more nuanced than the simple weighing of utility and disutility, and is
bounded by incomplete information, uncertainty, and the cognitive limits of the mind.19
This perspective of bounded rationality could also improve how we approach medical
decision-making at the level of the individual patient. Increasingly, shared decision making
is emphasized to ensure that individual patients can make “informed, evidence-based
decisions that are consistent with their values and preferences”.15, 20 While the science of
shared decision making has advanced our understanding of how to communicate
quantitative risk,15 the work by Fontana and Asaria and colleagues in this issue of
Circulation reminds us that we still lack evidence-based approaches to incorporate patient
preferences such as medication disutility into the shared decision making process. As our
understanding of cardiovascular risk continues to be refined, how to account for the
uncertain calculus of risk, benefits, and preferences at the individual level will be a central
challenge for the practice of personalized cardiovascular medicine.
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